CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Neukio Biotherapeutics
Main focus: Next-generation cell therapies for the treatment of cancer
Company stage: Pre-clinical
Diseases (gene editing): Haematological and solid cancers
Genome editing tool: Undisclosed
Funding stage: Private
Location: Shanghai, China
Website: https://www.neukio.com/en
Gene-editing partnerships: EdiGene
Neukio Biotherapeutics is a Shanghai-based start-up company, which aims to develop next-generation natural killer (NK) cell-based therapies. The company's developmental programmes are currently undisclosed, but it has recently formed a collaboration with EdiGene to utilise its gene-editing capabilities.
